title: Prevalence of transmitted HIV-1 drug resistance remains low in Guangxi, China, eight years after scale-up of highly-active antiretroviral therapy.
abstract: OBJECTIVE
  Highly-active antiretroviral therapy (HAART) was scaled up in Guangxi, China in 2005. The number of individuals receiving free HAART increased dramatically from June 2010 under the Guangxi Government's anti-HIV programme. We aimed to determine the prevalence of HIV-transmitted drug resistance (TDR) of Guangxi.
  
  
  METHODS
  HIV-positive, antiretroviral-naive individuals were recruited from the east (Hezhou), south (Qinzhou), west (Baise), north (Guilin) and centre (Laibin) of Guangxi. The pol gene of the virus from the individuals was analysed.
  
  
  RESULTS
  The overall prevalence of HIV TDR was 3.2% (7/216, 95% CI 0.9-5.5). The prevalence rates in Baise, Guilin, Hezhou, Qinzhou and Laibin are 4.9% (2/41, 95% CI -1.7 to 11.5), 2.3% (1/44, 95% CI -2.1 to 5.7), 4.7% (2/43, 95% CI -1.6 to 11.0), 2.6% (1/38, 95% CI -2.5 to 7.7) and 2.0% (1/50, 95% CI -1.9 to 5.9), respectively. No significant difference in the prevalence was found among them. No factors were found to be associated with TDR, including CD4 cell counts, viral loads and genotypes. The subtypes CRF01_AE, CRF07_BC, CRF08_BC and B were found. Subtype CRF08_BC is the predominant subtype in Baise while CRF01_AE is the predominant subtype elsewhere in Guangxi.
  
  
  CONCLUSIONS
  The prevalence of TDR in antiretroviral-naive patients in Guangxi remains low 8 years after scale-up of HAART.
authors.affiliation: Department of Public Health of Guangxi Zhuang Autonomous Region, Nanning, China.
authors.forename: Guojian
authors.initials: G
authors.lastname: Li
authors.forename: Shujia
authors.initials: S
authors.lastname: Liang
authors.forename: Tim J
authors.initials: TJ
authors.lastname: Harrison
authors.forename: Zhenzhu
authors.initials: Z
authors.lastname: Tang
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Shen
authors.forename: Xueyan
authors.initials: X
authors.lastname: Wang
authors.forename: Xinghua
authors.initials: X
authors.lastname: Wu
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.forename: Fuxiong
authors.initials: F
authors.lastname: Liang
authors.forename: Liushuai
authors.initials: L
authors.lastname: Feng
authors.forename: Jinye
authors.initials: J
authors.lastname: Yang
authors.forename: Zhongliao
authors.initials: Z
authors.lastname: Fang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D002681:China / Q000453:epidemiology; D024882:Drug Resistance, Viral; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D055815:Young Adult; D054302:pol Gene Products, Human Immunodeficiency Virus / Q000235:genetics
chemical_list: D044966:Anti-Retroviral Agents; D054302:pol Gene Products, Human Immunodeficiency Virus